2-(4-ethylphenyl)pyrazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(4-ethylphenyl)pyrazine
• 化学式: C₁₂H₁₂N₂
• mdl: MFCD28246350
• 分子量: 184.241
• InChiKey: OJTOANYUFFXNGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-ethylphenyl)pyrazine 在 potassium tert-butylate 、 sodium acetate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 27.0h， 生成
  参考文献：
  名称：

  Solid state fluorescent palladacycles with N-heterocyclic carbene-based ancillary ligands at room temperature

  摘要：

  Two pyrazine ligands 1-2 and their NHC-palladacycles 3-10 have been synthesized and fully characterized. Additionally, the detailed structures of 5-7 and 9 have been determined by X-ray diffraction and intermolecular pi center dot center dot center dot pi and C-H center dot center dot center dot X (Cl, N) interactions were found in their crystal structures. These palladacycles are fluorescent in both the solid state and solution at room temperature. (C) 2014 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2014.11.019
• 作为产物：
  描述：

  2-氯吡嗪 、 4-乙基苯硼酸 在 palladium diacetate 、 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 24.0h， 以87%的产率得到2-(4-ethylphenyl)pyrazine
  参考文献：
  名称：

  Solid state fluorescent palladacycles with N-heterocyclic carbene-based ancillary ligands at room temperature

  摘要：

  Two pyrazine ligands 1-2 and their NHC-palladacycles 3-10 have been synthesized and fully characterized. Additionally, the detailed structures of 5-7 and 9 have been determined by X-ray diffraction and intermolecular pi center dot center dot center dot pi and C-H center dot center dot center dot X (Cl, N) interactions were found in their crystal structures. These palladacycles are fluorescent in both the solid state and solution at room temperature. (C) 2014 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2014.11.019

文献信息

• Direct C–H photoarylation of diazines using aryldiazonium salts and visible-light
  作者：Rodrigo C. Silva、Lucas F. Villela、Timothy J. Brocksom、Kleber T. de Oliveira

  DOI：10.1039/d0ra06876d

  日期：——

  demonstrate the efficacy of this protocol by the scope with electron-donor, -neutral, and -withdrawing groups attached at the ortho, meta, and para positions of the aryldiazonium salts; the results are better than those reported for ruthenium-complex mediated photoarylations. Additionally, we demonstrate the robustness of this methodology with a 5 mmol scaled-up experiment. Mechanistic studies were carried

  在本研究中，描述了在可见光照射（蓝色 LED）下吡嗪与芳基重氮盐的直接 C-H 光芳基化，还涵盖了其他例子，包括嘧啶和哒嗪的光芳基化。仅通过混合和辐照反应，无需额外的光催化剂即可以高达 84% 的产率制备相应的芳基二嗪。我们通过在邻位、元位和对位连接的电子供体、中性和撤回基团的范围来证明该协议的有效性芳基重氮盐的位置；结果比报道的钌络​​合物介导的光芳基化的结果要好。此外，我们通过 5 mmol 放大实验证明了该方法的稳健性。进行了机理研究，以支持电子供体-受体 (EDA) 复合物光催化方法的提议，同时也强调了溶剂在 EDA 复合物形成中的关键作用。
• BRIDGED CARBAMATE MACROLIDES
  申请人：Kim Heejin

  公开号：US20080027012A1

  公开（公告）日：2008-01-31

  The present invention discloses compounds of formulae (I) and (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了式(I)和(II)的化合物或其药学上可接受的盐、酯或前药：这些化合物具有抗菌性能。本发明还涉及含有上述化合物的药物组合物，用于治疗需要抗生素治疗的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• C-9 ALKENYLIDINE BRIDGED MACROLIDES
  申请人：Phan Ly Tam

  公开号：US20080119418A1

  公开（公告）日：2008-05-22

  The present invention discloses compounds of formulae (I), (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明揭示了以下化合物的公式（I），（II）或其药学上可接受的盐，酯或前药：具有抗菌性质。本发明还涉及包括上述化合物的制药组合物，用于治疗需要抗生素治疗的受体。本发明还涉及通过给予包含本发明化合物的制药组合物来治疗受体的细菌感染的方法。本发明还包括制备本发明化合物的方法。
• 3,6-Bridged 9,12-oxolides
  申请人：Or Sun Yat

  公开号：US20070232554A1

  公开（公告）日：2007-10-04

  The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明揭示了公式（I）的化合物或其药学上可接受的盐、酯或前药：具有抗菌性能。本发明还涉及包含上述化合物的制药组合物，用于治疗需要抗生素治疗的受体。本发明还涉及通过给予包含本发明化合物的制药组合物来治疗受体的细菌感染的方法。本发明还包括制备本发明化合物的方法。
• 6-11 Bicyclic Ketolide Derivatives
  申请人：Or Yat Sun

  公开号：US20070244160A1

  公开（公告）日：2007-10-18

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.